Payment overview · 2025
General Payments
$256.71
13 reported records · 7 companies
Healthcare provider profile · identity verified
Deepak C Patel, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CORSICANA, TX · NPI 1114989910
Verified facts
What the public records show
CMS Open Payments records show Deepak C Patel, MD received $256.71 in general payments during 2025 across 13 reported records.
Novo Nordisk Inc accounted for 36.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 379 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $93.42 | 36.4% | 5 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $36.32 | 14.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.57 | 11.9% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $29.47 | 11.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.09 | 9.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.91 | 8.9% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $20.93 | 8.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $256.71 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $52.63 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $40.79 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $36.32 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.57 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.57 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $29.47 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $23.09 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $20.93 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 55 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
55 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
379 | 54 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 813 | 140 |
| Atorvastatin Calcium | Atorvastatin Calcium | 752 | 147 |
| Amlodipine Besylate | Amlodipine Besylate | 711 | 132 |
| Gabapentin | Gabapentin | 704 | 100 |
| Furosemide | Furosemide | 650 | 114 |
| Potassium Chloride | Potassium Chloride | 474 | 92 |
| Lisinopril | Lisinopril | 451 | 91 |
| Omeprazole | Omeprazole | 437 | 94 |
| Tramadol Hcl | Tramadol Hcl | 402 | 89 |
| Eliquis | Apixaban | 379 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 372 | 70 |
| Losartan Potassium | Losartan Potassium | 367 | 81 |
| Citalopram Hbr | Citalopram Hydrobromide | 354 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 352 | 70 |
| Divalproex Sodium | Divalproex Sodium | 336 | 49 |
| Trazodone Hcl | Trazodone Hcl | 317 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 308 | 60 |
| Carvedilol | Carvedilol | 284 | 52 |
| Mirtazapine | Mirtazapine | 284 | 59 |
| Simvastatin | Simvastatin | 258 | 64 |
| Famotidine | Famotidine | 254 | 45 |
| Buspirone Hcl | Buspirone Hcl | 241 | 27 |
| Donepezil Hcl | Donepezil Hcl | 235 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 220 | 45 |
| Metformin Hcl | Metformin Hcl | 218 | 55 |
| Sertraline Hcl | Sertraline Hcl | 204 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 202 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 191 | 31 |
| Alprazolam | Alprazolam | 183 | 35 |
| Temazepam | Temazepam | 180 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 175 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 174 | 50 |
| Tizanidine Hcl | Tizanidine Hcl | 163 | 34 |
| Meloxicam | Meloxicam | 162 | 39 |
| Xarelto | Rivaroxaban | 156 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 151 | 23 |
| Memantine Hcl | Memantine Hcl | 151 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 150 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 149 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 145 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 144 | 37 |
| Allopurinol | Allopurinol | 136 | 28 |
| Levetiracetam | Levetiracetam | 133 | 18 |
| Lorazepam | Lorazepam | 133 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 133 | 17 |
| Glipizide | Glipizide | 129 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 121 | 36 |
| Ropinirole Hcl | Ropinirole Hcl | 118 | 16 |
| Myrbetriq | Mirabegron | 114 | suppressed |
| Clonazepam | Clonazepam | 111 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 110 | 25 |
| Spironolactone | Spironolactone | 106 | 15 |
| Montelukast Sodium | Montelukast Sodium | 104 | 17 |
| Alendronate Sodium | Alendronate Sodium | 98 | 19 |
| Bydureon Bcise | Exenatide Microspheres | 97 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 96 | 24 |
| Baclofen | Baclofen | 91 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 88 | 64 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 86 | 16 |
| Latanoprost | Latanoprost | 83 | 20 |
| Clonidine Hcl | Clonidine Hcl | 82 | 23 |
| Tresiba Flextouch U-200 | Insulin Degludec | 81 | 15 |
| Amiodarone Hcl | Amiodarone Hcl | 77 | 12 |
| Finasteride | Finasteride | 77 | 21 |
| Jardiance | Empagliflozin | 77 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 76 | 17 |
| Januvia | Sitagliptin Phosphate | 73 | suppressed |
| Lovastatin | Lovastatin | 73 | 20 |
| Ceftriaxone | Ceftriaxone Sodium | 71 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 70 | 52 |
| Aripiprazole | Aripiprazole | 65 | suppressed |
| Torsemide | Torsemide | 63 | 11 |
| Tradjenta | Linagliptin | 62 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 61 | 11 |
| Risperidone | Risperidone | 61 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 12 |
| Glimepiride | Glimepiride | 60 | 19 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 58 | 44 |
| Ezetimibe | Ezetimibe | 57 | 16 |
| Lidocaine Hcl | Lidocaine Hcl | 57 | 36 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 55 | 14 |
| Ozempic | Semaglutide | 55 | 11 |
| Benztropine Mesylate | Benztropine Mesylate | 53 | suppressed |
| Fluconazole | Fluconazole | 53 | 20 |
| Vascepa | Icosapent Ethyl | 53 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | suppressed |
| Atenolol | Atenolol | 50 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 50 | suppressed |
| Methocarbamol | Methocarbamol | 50 | 12 |
| Celecoxib | Celecoxib | 48 | 12 |
| Nystatin | Nystatin | 48 | 23 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 47 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | 17 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 46 | 18 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 43 | 16 |
| Prednisone | Prednisone | 43 | 20 |
| Sucralfate | Sucralfate | 43 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | suppressed |
| Ketoconazole | Ketoconazole | 41 | 16 |
| Sodium Chloride | 0.9 % Sodium Chloride | 41 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 20 |
| Pregabalin | Pregabalin | 39 | 11 |
| Lactulose | Lactulose | 38 | 13 |
| Methenamine Hippurate | Methenamine Hippurate | 38 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 20 |
| Diltiazem Hcl | Diltiazem Hcl | 37 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 37 | suppressed |
| Lacosamide | Lacosamide | 37 | suppressed |
| Novolog Flexpen | Insulin Aspart | 37 | 13 |
| Mupirocin | Mupirocin | 36 | 21 |
| Nebivolol Hcl | Nebivolol Hcl | 36 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Diazepam | Diazepam | 35 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 34 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 33 | suppressed |
| Cephalexin | Cephalexin | 32 | 21 |
| Methylprednisolone | Methylprednisolone | 32 | 29 |
| Metoclopramide Hcl | Metoclopramide Hcl | 32 | suppressed |
| Nystop | Nystatin | 32 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 23 |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Azithromycin | Azithromycin | 31 | 23 |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Phenobarbital | Phenobarbital | 31 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Levemir Flexpen | Insulin Detemir | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Lidocaine | Lidocaine | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 11 |
| Nifedipine Er | Nifedipine | 27 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 26 | suppressed |
| Bumetanide | Bumetanide | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 18 |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 26 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Nyamyc | Nystatin | 25 | 14 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Xifaxan | Rifaximin | 24 | suppressed |
| Anastrozole | Anastrozole | 23 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 23 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 23 | 13 |
| Santyl | Collagenase Clostridium Hist. | 22 | 15 |
| Cefuroxime | Cefuroxime Axetil | 21 | 14 |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 21 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 15 |
| Carbamazepine | Carbamazepine | 18 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 17 | 15 |
| Fluphenazine Hcl | Fluphenazine Hcl | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 16 | suppressed |
| Levemir | Insulin Detemir | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 15 | 15 |
| Olanzapine | Olanzapine | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Paroxetine Cr | Paroxetine Hcl | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $256.71 · 13 records | Novo Nordisk Inc | INSPIRE, LifeVest, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, VYNDAQEL, WATCHMAN FLX, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error